Questions about Atrial Fibrillation? Get answers from our expert.

Vancocin

Pronunciation

Generic Name: vancomycin hydrochloride
Dosage Form: capsule

Vancocin® (vancomycin hydrochloride, USP) CAPSULES

Indications and Usage for Vancocin

Vancocin CAPSULES are indicated for the treatment of C. difficile-associated diarrhea. Vancocin CAPSULES are also used for the treatment of enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains). Parenteral administration of vancomycin is not effective for the above infections; therefore, Vancocin CAPSULES must be given orally for these infections.

Orally administered Vancocin is not effective for other types of infections.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Vancocin CAPSULES and other antibacterial drugs, Vancocin CAPSULES should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Dosage and Administration

Adults

Vancocin CAPSULES are used in treating C. difficile-associated diarrhea and staphylococcal enterocolitis.

  • C. difficile-associated diarrhea: The recommended dose is 125 mg administered orally 4 times daily for 10 days.
  • Staphylococcal enterocolitis: Total daily dosage is 500 mg to 2 g administered orally in 3 or 4 divided doses for 7 to 10 days.

Pediatric Patients

The usual daily dosage is 40 mg/kg in 3 or 4 divided doses for 7 to 10 days. The total daily dosage should not exceed 2 g.

Slideshow: Worried About Ebola? You’re More Likely to Get These 10 Serious Infections

Dosage Forms and Strengths

Vancocin 125 mg* CAPSULES have an opaque blue cap and opaque brown body imprinted with “3125” on the cap and “Vancocin HCL 125 MG” on the body in white ink.

Vancocin 250 mg* CAPSULES have an opaque blue cap and opaque lavender body imprinted with “3126” on the cap and “Vancocin HCL 250 MG” on the body in white ink.

*Equivalent to vancomycin.

Contraindications

Vancocin CAPSULES are contraindicated in patients with known hypersensitivity to vancomycin.

Warnings and Precautions

Oral Use Only

This preparation for the treatment of colitis is for oral use only and is not systemically absorbed. Vancocin CAPSULES must be given orally for treatment of staphylococcal enterocolitis and Clostridium difficile-associated diarrhea. Orally administered Vancocin CAPSULES are not effective for other types of infections.

Parenteral administration of vancomycin is not effective for treatment of staphylococcal enterocolitis and C. difficile-associated diarrhea. If parenteral vancomycin therapy is desired, use an intravenous preparation of vancomycin and consult the package insert accompanying that preparation.

Potential for Systemic Absorption

Clinically significant serum concentrations have been reported in some patients who have taken multiple oral doses of Vancocin for active C. difficile-associated diarrhea. Some patients with inflammatory disorders of the intestinal mucosa also may have significant systemic absorption of vancomycin. These patients may be at risk for the development of adverse reactions associated with higher doses of Vancocin; therefore, monitoring of serum concentrations of vancomycin may be appropriate in some instances, e.g., in patients with renal insufficiency and/or colitis or in those receiving concomitant therapy with an aminoglycoside antibiotic.

Nephrotoxicity

Nephrotoxicity (e.g., reports of renal failure, renal impairment, blood creatinine increased) has occurred following oral Vancocin therapy in randomized controlled clinical studies, and can occur either during or after completion of therapy. The risk of nephrotoxicity is increased in patients >65 years of age (see ADVERSE REACTIONS, Clinical Trial Experience [6.1] and USE IN SPECIFIC POPULATIONS, Geriatric Use [8.5]).

In patients >65 years of age, including those with normal renal function prior to treatment, renal function should be monitored during and following treatment with Vancocin to detect potential vancomycin induced nephrotoxicity.

Ototoxicity

Ototoxicity has occurred in patients receiving vancomycin. It may be transient or permanent. It has been reported mostly in patients who have been given excessive intravenous doses, who have an underlying hearing loss, or who are receiving concomitant therapy with another ototoxic agent, such as an aminoglycoside. Serial tests of auditory function may be helpful in order to minimize the risk of ototoxicity (see ADVERSE REACTIONS, Postmarketing Experience [6.2]).

Superinfection

Use of Vancocin may result in the overgrowth of nonsusceptible bacteria. If superinfection occurs during therapy, appropriate measures should be taken.

Development of Drug-Resistant Bacteria

Prescribing Vancocin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug resistant bacteria.

Adverse Reactions

Clinical Trial Experience

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

The data described below reflect exposure to Vancocin in 260 adult subjects in two Phase 3 clinical trials for the treatment of diarrhea associated with C. difficile. In both trials, subjects received Vancocin 125 mg orally four times daily. The mean duration of treatment was 9.4 days. The median age of patients was 67, ranging between 19 and 96 years of age. Patients were predominantly Caucasian (93%) and 52% were male.

Adverse reactions occurring in ≥ 5% of Vancocin-treated subjects are shown in Table 1. The most common adverse reactions associated with Vancocin (≥ 10%) were nausea, abdominal pain, and hypokalemia.

Table 1: Common (≥ 5%) Adverse Reactionsa for Vancocin Reported in Clinical Trials for Treatment of Diarrhea Associated with C. difficile

a Adverse reaction rates were derived from the incidence of treatment-emergent adverse events.

System/Organ Class Adverse Reaction Vancocin
% (N=260)
Gastrointestinal disorders Nausea
Abdominal pain
Vomiting
Diarrhea
Flatulence
17
15
9
9
8

General disorders and administration site conditions Pyrexia
Edema peripheral
Fatigue
9
6
5
Infections and infestations Urinary tract infection 8
Metabolism and nutrition disorders Hypokalemia 13
Musculoskeletal and connective tissue disorders Back pain 6
Nervous system disorders Headache
7

Nephrotoxicity (e.g., reports of renal failure, renal impairment, blood creatinine increased) occurred in 5% of subjects treated with Vancocin. Nephrotoxicity following Vancocin typically first occurred within one week after completion of treatment (median day of onset was Day 16). Nephrotoxicity following Vancocin occurred in 6% of subjects >65 years of age and 3% of subjects ≤65 years of age (see WARNINGS AND PRECAUTIONS, Nephrotoxicity [5.3]).

The incidences of hypokalemia, urinary tract infection, peripheral edema, insomnia, constipation, anemia, depression, vomiting, and hypotension were higher among subjects >65 years of age than in subjects ≤65 years of age (see USE IN SPECIFIC POPULATIONS, Geriatric Use [8.5]).

Discontinuation of study drug due to adverse events occurred in 7% of subjects treated with Vancocin. The most common adverse events leading to discontinuation of Vancocin were C. difficile colitis (<1%), nausea (<1%), and vomiting (<1%).

Postmarketing Experience

The following adverse reactions have been identified during post-approval use of Vancocin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Ototoxicity: Cases of hearing loss associated with intravenously administered vancomycin have been reported. Most of these patients had kidney dysfunction or a preexisting hearing loss or were receiving concomitant treatment with an ototoxic drug (see WARNINGS AND PRECAUTIONS, Ototoxicity [5.4]). Vertigo, dizziness, and tinnitus have been reported.

Hematopoietic: Reversible neutropenia, usually starting 1 week or more after onset of intravenous therapy with vancomycin or after a total dose of more than 25 g, has been reported for several dozen patients. Neutropenia appears to be promptly reversible when vancomycin is discontinued. Thrombocytopenia has been reported.

Miscellaneous: Patients have been reported to have had anaphylaxis, drug fever, chills, nausea, eosinophilia, rashes (including exfoliative dermatitis), Stevens-Johnson syndrome, toxic epidermal necrolysis, and rare cases of vasculitis in association with the administration of vancomycin.

A condition has been reported that is similar to the IV–induced syndrome with symptoms consistent with anaphylactoid reactions, including hypotension, wheezing, dyspnea, urticaria, pruritus, flushing of the upper body (“Red Man Syndrome”), pain and muscle spasm of the chest and back. These reactions usually resolve within 20 minutes but may persist for several hours.

Drug Interactions

No drug interaction studies have been conducted.

USE IN SPECIFIC POPULATIONS

Pregnancy

Pregnancy Category B – The highest doses of vancomycin tested were not teratogenic in rats given up to 200 mg/kg/day IV (1180 mg/m2 or 1 times the recommended maximum human dose based on body surface area) or in rabbits given up to 120 mg/kg/day IV (1320 mg/m2 or 1.1 times the recommended maximum human dose based body surface area). No effects on fetal weight or development were seen in rats at the highest dose tested or in rabbits given 80 mg/kg/day (880 mg/m2 or 0.74 times the recommended maximum human dose based on body surface area).

In a controlled clinical study, the potential ototoxic and nephrotoxic effects of vancomycin on infants were evaluated when the drug was administered intravenously to pregnant women for serious staphylococcal infections complicating intravenous drug abuse. Vancomycin was found in cord blood. No sensorineural hearing loss or nephrotoxicity attributable to vancomycin was noted. One infant whose mother received vancomycin in the third trimester experienced conductive hearing loss that was not attributed to the administration of vancomycin. Because the number of subjects treated in this study was limited and vancomycin was administered only in the second and third trimesters, it is not known whether vancomycin causes fetal harm. Because animal reproduction studies are not always predictive of human response, Vancocin should be given to a pregnant woman only if clearly needed.

Nursing Mothers

Vancomycin is excreted in human milk based on information obtained with the intravenous administration of vancomycin. However, systemic absorption of vancomycin is very low following oral administration of Vancocin (see CLINICAL PHARMACOLOGY, Pharmacokinetics [12.3]). It is not known whether vancomycin is excreted in human milk, as no studies of vancomycin concentration in human milk after oral administration have been done. Caution should be exercised when Vancocin is administered to a nursing woman. Because of the potential for adverse events, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

Geriatric Use

In clinical trials, 54% of Vancocin-treated subjects were >65 years of age. Of these, 40% were between the ages of >65 and 75, and 60% were >75 years of age.

Clinical studies with Vancocin in diarrhea associated with Clostridium difficile have demonstrated that geriatric subjects are at increased risk of developing nephrotoxicity following treatment with oral Vancocin, which may occur during or after completion of therapy. In patients >65 years of age, including those with normal renal function prior to treatment, renal function should be monitored during and following treatment with Vancocin to detect potential vancomycin induced nephrotoxicity (see WARNINGS AND PRECAUTIONS, Nephrotoxicity [5.3]; ADVERSE REACTIONS, Clinical Trial Experience [6.1] and CLINICAL STUDIES, Diarrhea Associated with Clostridium difficile [14.1]).

Patients >65 years of age may take longer to respond to therapy compared to patients ≤65 years of age (see CLINICAL STUDIES, Diarrhea Associated with Clostridium difficile [14.1]). Clinicians should be aware of the importance of appropriate duration of Vancocin treatment in patients >65 years of age and not discontinue or switch to alternative treatment prematurely.

Overdosage

Supportive care is advised, with maintenance of glomerular filtration. Vancomycin is poorly removed by dialysis. Hemofiltration and hemoperfusion with polysulfone resin have been reported to result in increased vancomycin clearance.

To obtain up-to-date information about the treatment of overdose, a good resource is your certified Regional Poison Control Center. Telephone numbers of certified poison control centers are listed in the Physicians' Desk Reference (PDR). In managing overdosage, consider the possibility of multiple drug overdoses, interaction among drugs, and unusual drug kinetics.

Vancocin Description

Vancocin CAPSULES for oral administration contain chromatographically purified vancomycin hydrochloride, a tricyclic glycopeptide antibiotic derived from Amycolatopsis orientalis (formerly Nocardia orientalis), which has the chemical formula C66H75Cl2N9O24•HCl. The molecular weight of vancomycin hydrochloride is 1485.73; 500 mg of the base is equivalent to 0.34 mmol.

The capsules contain vancomycin hydrochloride equivalent to 125 mg (0.08 mmol) or 250 mg (0.17 mmol) vancomycin. The capsules also contain F D & C Blue No. 2, gelatin, iron oxide, polyethylene glycol, titanium dioxide, and other inactive ingredients.

Vancomycin hydrochloride has the structural formula:

Vancocin - Clinical Pharmacology

Mechanism of Action

Vancomycin is an antibacterial drug (see CLINICAL PHARMACOLOGY, Microbiology [12.4]).

Pharmacokinetics

Vancomycin is poorly absorbed after oral administration. During multiple dosing of 250 mg every 8 hours for 7 doses, fecal concentrations of vancomycin in volunteers exceeded 100 mg/kg in the majority of samples. No blood concentrations were detected and urinary recovery did not exceed 0.76%. In anephric subjects with no inflammatory bowel disease who received vancomycin oral solution 2 g for 16 days, blood concentrations of vancomycin were less than or equal to 0.66 μg/mL in 2 of 5 subjects. No measurable blood concentrations were attained in the other 3 subjects. Following doses of 2 g daily, concentrations of drug were >3100 mg/kg in the feces and <1 μg/mL in the serum of subjects with normal renal function who had C. difficile-associated diarrhea. After multiple-dose oral administration of vancomycin, measurable serum concentrations may occur in patients with active C. difficile-associated diarrhea, and, in the presence of renal impairment, the possibility of accumulation exists. It should be noted that the total systemic and renal clearances of vancomycin are reduced in the elderly (see USE IN SPECIFIC POPULATIONS, Geriatric Use [8.5]).

Microbiology

Mechanism of action

The bactericidal action of vancomycin against Staphylococcus aureus and the vegetative cells of Clostridium difficile results primarily from inhibition of cell-wall biosynthesis. In addition, vancomycin alters bacterial-cell-membrane permeability and RNA synthesis.

Mechanism of resistance

 
Staphylococcus aureus
 
S. aureus isolates with vancomycin minimal inhibitory concentrations (MICs) as high as 1024 mcg/mL have been reported.
 
The exact mechanism of this resistance is not clear but is believed to be due to cell wall thickening and potentially the transfer of genetic material.
 
Clostridium difficile
 
Isolates of C. difficile generally have vancomycin MICs of <1 mcg/mL, however vancomycin MICs ranging from 4 mcg/mL to 16 mcg/mL have been reported. The mechanism which mediates C. difficile's decreased susceptibility to vancomycin has not been fully elucidated.

Vancomycin has been shown to be active against susceptible isolates of the following bacteria in clinical infections as described in the INDICATIONS AND USAGE section.

Gram-positive bacteria

 
Staphylococcus aureus (including methicillin-resistant isolates) associated with enterocolitis

Anaerobic Gram-positive bacteria

 
Clostridium difficile isolates associated with C. difficile associated diarrhea.

Nonclinical Toxicology

Carcinogenesis, Mutagenesis, Impairment of Fertility

No long-term carcinogenesis studies in animals have been conducted.

At concentrations up to 1000 μg/mL, vancomycin had no mutagenic effect in vitro in the mouse lymphoma forward mutation assay or the primary rat hepatocyte unscheduled DNA synthesis assay. The concentrations tested in vitro were above the peak plasma vancomycin concentrations of 20 to 40 μg/mL usually achieved in humans after slow infusion of the maximum recommended dose of 1 g. Vancomycin had no mutagenic effect in vivo in the Chinese hamster sister chromatid exchange assay (400 mg/kg IP) or the mouse micronucleus assay (800 mg/kg IP).

No definitive fertility studies have been conducted.

Clinical Studies

Diarrhea Associated with Clostridium difficile

In two trials, Vancocin 125 mg orally four times daily for 10 days was evaluated in 266 adult subjects with C. difficile-associated diarrhea (CDAD). Enrolled subjects were 18 years of age or older and received no more than 48 hours of treatment with oral Vancocin or oral/intravenous metronidazole in the 5 days preceding enrollment. CDAD was defined as ≥3 loose or watery bowel movements within the 24 hours preceding enrollment, and the presence of either C. difficile toxin A or B, or pseudomembranes on endoscopy within the 72 hours preceding enrollment. Subjects with fulminant C. difficile disease, sepsis with hypotension, ileus, peritoneal signs or severe hepatic disease were excluded.

Efficacy analyses were performed on the Full Analysis Set (FAS), which included randomized subjects who received at least one dose of Vancocin and had any post-dosing investigator evaluation data (N=259; 134 in Trial 1 and 125 in Trial 2).

The demographic profile and baseline CDAD characteristics of enrolled subjects were similar in the two trials. Vancocin-treated subjects had a median age of 67 years, were mainly white (93%), and male (52%). CDAD was classified as severe (defined as 10 or more unformed bowel movements per day or WBC ≥15000/mm3) in 25% of subjects, and 47% were previously treated for CDAD.

Efficacy was assessed by using clinical success, defined as diarrhea resolution and the absence of severe abdominal discomfort due to CDAD, on Day 10. An additional efficacy endpoint was the time to resolution of diarrhea, defined as the beginning of diarrhea resolution that was sustained through the end of the prescribed active treatment period.

The results for clinical success for Vancocin-treated subjects in both trials are shown in Table 2.

Table 2: Clinical Success Rates (Full Analysis Set)
Clinical Success Rate 95% Confidence Interval
Vancocin % (N)
Trial 1 81.3 (134) (74.4, 88.3)
Trial 2 80.8 (125) (73.5, 88.1)

The median time to resolution of diarrhea was 5 days and 4 days in Trial 1 and Trial 2, respectively. For subjects older than 65 years of age, the median time to resolution was 6 days and 4 days in Trial 1 and Trial 2, respectively. In subjects with diarrhea resolution at end-of-treatment with Vancocin, recurrence of CDAD during the following four weeks occurred in 25 of 107 (23%) and 18 of 102 (18%) in Trial 1 and Trial 2, respectively.

Restriction Endonuclease Analysis (REA) was used to identify C. difficile baseline isolates in the BI group. In Trial 1, the Vancocin-treated subjects were classified at baseline as follows 31 (23%) with BI strain, 69 (52%) with non-BI strain, and 34 (25%) with unknown strain.  Clinical success rates were 87% for BI strain, 81% for non-BI strain, and 76% for unknown strain.  In subjects with diarrhea resolution at end-of treatment with Vancocin, recurrence of CDAD during the following four weeks occurred in 7 of 26 subjects with BI strain, 12 of 56 subjects with non-BI strain, and 6 of 25 subjects with unknown strain.

How Supplied/Storage and Handling

Vancocin CAPSULES are available in:

The 125 mg* capsules have an opaque blue cap and opaque brown body imprinted with “3125” on the cap and “Vancocin HCL 125 MG” on the body in white ink.  A carton contains 2 blister packs. Each blister pack contains 10 capsules for a total of 20 capsules per carton.  NDC 66593-3125-2 (PU3125)

The 250 mg* capsules have an opaque blue cap and opaque lavender body imprinted with “3126” on the cap and “Vancocin HCL 250 MG” on the body in white ink.  A carton contains 2 blister packs. Each blister pack contains 10 capsules for a total of 20 capsules per carton. NDC 66593-3126-2 (PU3126)

Store at controlled room temperature, 59° to 86°F (15° to 30°C).

*Equivalent to vancomycin.

Patient Counseling Information

Patients should be counseled that antibacterial drugs including Vancocin should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Vancocin is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Vancocin or other antibacterial drugs in the future.

________________________________________________________________________

Vancocin® is a registered U.S. trademark owned by ViroPharma Incorporated.

Rx Only
© ViroPharma Incorporated 2005. All rights reserved.
Distributed by: ViroPharma Incorporated, Exton, PA 19341, USA

Rev. 12/2011

VIROPHARMA®
INCORPORATED

Blister Pack Label 125 mg

VACNOCIN®HCI

vancomycin hydrochloride

Equiv. to 125 mg vancomycin

Carton Label 125 mg

Equiv. to 125 mg vancomycin

VACNOCIN®

(vancomycin hydrochloride capsules, USP)

Rx only

Not a Child Resistant Container

20 CAPSULES No. 3125

NDC 66593-3125-2 (125mg)

VIROPHARMA®

INCORPORATED

Blister Pack Label 250 mg

VACNOCIN®HCI

vancomycin hydrochloride

Equiv. to 250 mg vancomycin

Carton Label 250 mg

Equiv. to 250 mg vancomycin

VACNOCIN®

(vancomycin hydrochloride capsules, USP)

Rx only

Not a Child Resistant Container

20 CAPSULES No. 3125

NDC 66593-3126-2 (250mg)

VIROPHARMA®

INCORPORATED

Vancocin 
vancomycin hydrochloride capsule
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:66593-3125
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
vancomycin hydrochloride (vancomycin) vancomycin 125 mg
Inactive Ingredients
Ingredient Name Strength
FD&C Blue NO. 2  
gelatin  
Ferric Oxide Red  
Ferric Oxide Yellow  
polyethylene glycols  
titanium dioxide  
Product Characteristics
Color BLUE (blue) , BROWN (brown) Score no score
Shape CAPSULE (CAPSULE) Size 18mm
Flavor Imprint Code 3125
Contains         
Packaging
# Item Code Package Description
1 NDC:66593-3125-2 2 BLISTER PACK (2 BLISTER PACK) in 1 BOX
1 10 CAPSULE (10 CAPSULE) in 1 BLISTER PACK
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA050606 04/15/1986
Vancocin 
vancomycin hydrochloride capsule
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:66593-3126
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
vancomycin hydrochloride (vancomycin) vancomycin 250 mg
Inactive Ingredients
Ingredient Name Strength
FD&C Blue NO. 2  
gelatin  
Ferric Oxide Red  
Ferrosoferric Oxide  
polyethylene glycols  
titanium dioxide  
Product Characteristics
Color BLUE (blue) , PURPLE (lavender) Score no score
Shape CAPSULE (CAPSULE) Size 22mm
Flavor Imprint Code 3126
Contains         
Packaging
# Item Code Package Description
1 NDC:66593-3126-2 2 BLISTER PACK (2 BLISTER PACK) in 1 BOX
1 10 CAPSULE (10 CAPSULE) in 1 BLISTER PACK
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA050606 04/15/1986
Labeler - ViroPharma (928902857)
Establishment
Name Address ID/FEI Operations
Norwich Pharmaceuticals, Inc. 132218731 MANUFACTURE(66593-3125, 66593-3126)
Establishment
Name Address ID/FEI Operations
Axellia Pharmaceuticals 305814345 API MANUFACTURE(66593-3125, 66593-3126)
Revised: 12/2011
 
ViroPharma
Hide
(web2)